01—Abstract
Summary
Summary of the 8-K/A filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories filed Amendment No. 1 to its October 31, 2024 Form 8-K solely to correct one figure in its third-quarter earnings release: the projected full-year 2024 comparable operating margin expansion is now 30 to 60 basis points, down from the originally printed 70 to 100 basis points.
The correction is confined to that range; the rest of the release, including the revenue, EPS, and cash flow outlook, is unchanged. Investors should treat the corrected 30 to 60 basis point figure as the operative guidance, since the original press release overstated it. The corrected range matches the comparable margin expansion shown in the outlook table, so the original printed range was an inconsistency rather than a change in management's view.
The underlying quarter was solid. Revenue rose 7% as reported and 6% organic to $976 milliona, with CAG Diagnostics recurring revenue up 7%, international recurring revenue up double digits, and Water up 13%. EPS was $2.80, up 11% as reported and 12% on a comparable basis, and reported operating margin expanded 110 basis points to 31.2%.
Management did cut 2024 revenue guidance by about $38 millionb at the midpoint, citing softer U.S. clinic visit and pet owner demand, while holding the EPS midpoint steady at $10.37 to $10.53. The main concerns for investors are demand trends in U.S. veterinary clinics and the $61.5 million second-quarter litigation accrual, which takes the total accrual on the royalty dispute to $89.0 million.
That charge drove a roughly $0.56c per share hit to 2024 EPS and about 160 basis points of reported margin impact. The amendment does not change any of these figures.
02—Key points
Key Highlights
- Corrected 2024 comparable operating margin expansion guidance is 30 to 60 basis points, down from 70 to 100 basis points in the original October 31, 2024 release; no other figures were changed.
- Q3 2024 revenue of $976 million rose 7% as reported and 6% organic, with CAG Diagnostics recurring revenue up 7% and international recurring revenue up roughly 10%.
- Q3 diluted EPS of $2.80 grew 11% as reported and 12% on a comparable basis; reported operating margin reached 31.2%, up 110 basis points.
- 2024 revenue guidance was cut to $3,865M–$3,890M (about $38M lower at midpoint), with organic growth now projected at 5.3%–6.0%, reflecting weaker U.S. clinical visit and demand trends.
- 2024 EPS guidance was narrowed to $10.37–$10.53 with the midpoint unchanged, offset by lower projected interest expense and tax rate.
- A $61.5M second-quarter litigation accrual (total $89.0M on an expired royalty license dispute) reduces 2024 EPS by $0.56 and reported margin by about 160 basis points.
- Free cash flow for the first nine months was $575M, and 2024 capex guidance was lowered to about $160M from about $180M.
03—Questions
Frequently Asked Questions
Why did IDEXX file this amended 8-K?
The company filed Amendment No. 1 solely to correct the projected 2024 comparable operating margin expansion in its earnings release. The original release stated 70 to 100 basis points, and the corrected figure is 30 to 60 basis points. The rest of the earnings release, including the financial statements and other guidance, is unchanged.
What is the corrected margin guidance and why does it matter?
Comparable operating margin expansion for full-year 2024 is now guided at 30 to 60 basis points, versus the previously printed 70 to 100. This is the figure investors should use. The corrected range matches the comparable margin expansion in the company's outlook table, so the error was a typo in the narrative rather than a change in management's expectations, but the gap is large enough to matter for anyone modeling margins.
Did IDEXX change its overall financial guidance?
Revenue guidance was lowered to $3,865M–$3,890M, a reduction of about $38M at midpoint, because of weaker U.S. veterinary clinic visits and pet owner demand. The EPS range was narrowed to $10.37–$10.53 with the midpoint unchanged. The amendment itself does not alter any of these numbers.
How significant is the litigation charge?
The company recorded a $61.5M discrete accrual in Q2 2024 tied to alleged underpayment of royalties under an expired patent license, bringing the total accrual to $89.0M. The charge reduces 2024 EPS by $0.56 and reported operating margin by about 160 basis points. The company notes the actual loss could be higher or lower than the accrual.
04—Continue